全文获取类型
收费全文 | 3008篇 |
免费 | 464篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 70篇 |
妇产科学 | 157篇 |
基础医学 | 307篇 |
口腔科学 | 52篇 |
临床医学 | 847篇 |
内科学 | 625篇 |
皮肤病学 | 27篇 |
神经病学 | 212篇 |
特种医学 | 128篇 |
外科学 | 431篇 |
综合类 | 23篇 |
一般理论 | 2篇 |
预防医学 | 150篇 |
眼科学 | 10篇 |
药学 | 128篇 |
中国医学 | 6篇 |
肿瘤学 | 305篇 |
出版年
2023年 | 17篇 |
2022年 | 38篇 |
2021年 | 62篇 |
2020年 | 24篇 |
2019年 | 48篇 |
2018年 | 94篇 |
2017年 | 125篇 |
2016年 | 139篇 |
2015年 | 140篇 |
2014年 | 141篇 |
2013年 | 192篇 |
2012年 | 153篇 |
2011年 | 178篇 |
2010年 | 127篇 |
2009年 | 135篇 |
2008年 | 156篇 |
2007年 | 152篇 |
2006年 | 144篇 |
2005年 | 133篇 |
2004年 | 134篇 |
2003年 | 104篇 |
2002年 | 76篇 |
2001年 | 74篇 |
2000年 | 76篇 |
1999年 | 63篇 |
1998年 | 29篇 |
1997年 | 33篇 |
1996年 | 44篇 |
1995年 | 29篇 |
1994年 | 25篇 |
1993年 | 25篇 |
1992年 | 66篇 |
1991年 | 61篇 |
1990年 | 47篇 |
1989年 | 42篇 |
1988年 | 44篇 |
1987年 | 38篇 |
1986年 | 34篇 |
1985年 | 36篇 |
1984年 | 23篇 |
1983年 | 20篇 |
1982年 | 23篇 |
1981年 | 9篇 |
1980年 | 9篇 |
1979年 | 21篇 |
1978年 | 13篇 |
1976年 | 13篇 |
1972年 | 12篇 |
1971年 | 13篇 |
1970年 | 14篇 |
排序方式: 共有3494条查询结果,搜索用时 0 毫秒
91.
92.
93.
94.
95.
M. Sue Kirkman MD Vanessa Jones Briscoe PhD NP CDE Nathaniel Clark MD MS RD Hermes Florez MD MPH PhD Linda B. Haas PHC RN CDE Jeffrey B. Halter MD Elbert S. Huang MD MPH Mary T. Korytkowski MD Medha N. Munshi MD Peggy Soule Odegard BS PharmD CDE Richard E. Pratley MD Carrie S. Swift MS RD BC‐ADM CDE 《Journal of the American Geriatrics Society》2012,60(12):2342-2356
96.
97.
98.
99.
Socorro Lupisan Kriengsak Limkittikul Nestor Sosa Pornthep Chanthavanich Véronique Bianco Yaela Baine Marie Van der Wielen Jacqueline M. Miller 《Clinical and Vaccine Immunology : CVI》2013,20(10):1499-1507
In this study, we compared the immunogenicities of two lots of meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) that differed in serogroup A polysaccharide (PS) O-acetylation levels and evaluated their immunogenicities and safety in comparison to a licensed ACWY polysaccharide vaccine (Men-PS). In this phase III, partially blinded, controlled study, 1,170 healthy subjects aged 18 to 25 years were randomized (1:1:1) to receive one dose of MenACWY-TT lot A (ACWY-A) (68% O-acetylation), MenACWY-TT lot B (ACWY-B) (92% O-acetylation), or Men-PS (82% O-acetylation). Immunogenicity was evaluated in terms of serum bactericidal activity using rabbit complement (i.e., rabbit serum bactericidal activity [rSBA]). Solicited symptoms, unsolicited adverse events (AEs), and serious AEs (SAEs) were recorded. The immunogenicities, in terms of rSBA geometric mean titers, were comparable for both lots of MenACWY-TT. The vaccine response rates across the serogroups were 79.1 to 97.0% in the two ACWY groups and 73.7 to 94.1% in the Men-PS group. All subjects achieved rSBA titers of ≥1:8 for all serogroups. All subjects in the two ACWY groups and 99.5 to 100% in the Men-PS group achieved rSBA titers of ≥1:128. Pain was the most common solicited local symptom and was reported more frequently in the ACWY group (53.9 to 54.7%) than in the Men-PS group (36.8%). The most common solicited general symptoms were fatigue and headache, which were reported by 28.6 to 30.3% and 26.9 to 31.0% of subjects, respectively. Two subjects reported SAEs; one SAE was considered to be related to vaccination (blighted ovum; ACWY-B group). The level of serogroup A PS O-acetylation did not affect vaccine immunogenicity. MenACWY-TT (lot A) was not inferior to Men-PS in terms of vaccine response and was well tolerated. 相似文献
100.
Amodio P Salari L Montagnese S Schiff S Neri D Bianco T Minazzato L 《World journal of gastroenterology : WJG》2012,18(19):2295-2299
Hepatitis C virus (HCV) hepatitis and other diseases related to HCV, such as cryoglobulinemia, lymphoma and renal failure, impair health-related quality of life (HRQoL). In addition, HCV per se might directly influence HRQoL via colonization of microglia in the brain or, indirectly, via the effect of systemic inflammatory cytokines which, in turn, can trigger brain interleukin production. The treatment of HCV-related disorders with interferon (IFN) has an effect on HRQoL. Initially, IFN causes a transient deterioration of HRQoL, due to the induction of depression and other side effects of treatment. Subsequently, the subjects who obtain a sustained virologic response experience an improvement in HRQoL. Only rarely does interferon treatment causes permanent detrimental effects on HRQoL, due to residual psychiatric or neurologic side effects. Liver transplantation is the only treatment for end-stage HCV-related liver disease. HRQoL generally improves massively a few months after transplantation, except in the case of serious complications of the transplant procedure. Furthermore, high levels of anxiety and neuroticism pre-transplant are associated with lower HRQoL one year after transplant. Additionally, six months after transplant, patients with HCV who experience virologic recurrence show significantly greater depression, anxiety, phobic anxiety, and paranoid ideation than anti-HCV-negative patients. In conclusion, optimal care for the overall well-being of patients with HCV infection requires adequate knowledge of their neurological and psychological status. 相似文献